Liothyronine
Cytomel, Liothyronine (liothyronine) is a small molecule pharmaceutical. Liothyronine was first approved as Cytomel on 1982-01-01. It is used to treat autoimmune thyroiditis, goiter, myxedema, thyroid neoplasms, and thyrotoxicosis in the USA. The pharmaceutical is active against thyroid hormone receptor beta and thyroid hormone receptor alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cytomel, Liothyronine (discontinued: Liothyronine, Triostat)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Liothyronine sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CYTOMEL | King Pharmaceuticals | N-010379 RX | 1982-01-01 | 3 products, RLD |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adthyza | unapproved drug other | 2023-02-23 |
| adthyza thyroid | unapproved drug other | 2023-12-08 |
| cytomel | New Drug Application | 2019-07-24 |
| liothyronine sodium | ANDA | 2024-11-05 |
| np thyroid | unapproved drug other | 2021-05-11 |
| np thyroid 120 | unapproved drug other | 2024-10-15 |
| np thyroid 15 | unapproved drug other | 2024-10-15 |
| np thyroid 30 | unapproved drug other | 2024-10-29 |
| np thyroid 60 | unapproved drug other | 2024-10-15 |
| np thyroid 90 | unapproved drug other | 2024-10-15 |
Show 1 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
720 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | 1 | 4 | — | 2 | 16 | 23 |
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | 1 | 4 | 2 | 4 | 12 | 22 |
| Depression | D003863 | — | F33.9 | 1 | — | 2 | 4 | 11 | 18 |
| Syndrome | D013577 | — | — | 1 | 1 | 1 | 2 | 11 | 16 |
| Prostatic neoplasms | D011471 | — | C61 | 4 | 2 | 4 | 1 | 7 | 16 |
| Recurrence | D012008 | — | — | 2 | 3 | 1 | 1 | 6 | 12 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | 2 | 3 | 6 | 12 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 3 | — | 2 | 7 | 12 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | — | 3 | 7 | 11 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 2 | 1 | — | 1 | 5 | 9 |
Show 46 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 8 | 2 | — | 24 | 35 |
| Rectal neoplasms | D012004 | — | — | 2 | 15 | 4 | — | 10 | 31 |
| Postoperative pain | D010149 | — | G89.18 | 1 | 1 | 1 | — | 18 | 20 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 5 | 2 | — | 10 | 19 |
| Carcinoma | D002277 | — | C80.0 | 4 | 8 | 4 | — | 6 | 19 |
| Neoplasms | D009369 | — | C80 | — | 4 | 1 | — | 12 | 17 |
| Colorectal neoplasms | D015179 | — | — | — | 3 | 1 | — | 10 | 14 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | — | 1 | — | 6 | 10 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 3 | 2 | — | 4 | 10 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | 1 | — | 8 | 9 |
Show 31 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 19 | 1 | — | — | 8 | 27 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 2 | 1 | — | — | 17 | 19 |
| Hallucinations | D006212 | HP_0000738 | F06.0 | — | 1 | — | — | 9 | 10 |
| Covid-19 | D000086382 | — | — | — | 2 | — | — | 7 | 9 |
| Inflammation | D007249 | MP_0001845 | — | 1 | 1 | — | — | 7 | 9 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | — | — | 7 | 8 |
| Heart failure | D006333 | HP_0001635 | I50 | 3 | 4 | — | — | 3 | 7 |
| Head and neck neoplasms | D006258 | — | — | 1 | 1 | — | — | 4 | 6 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 3 | — | — | 3 | 6 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 3 | — | — | 2 | 5 |
Show 55 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | HP_0012532 | — | 1 | — | — | — | 6 | 7 |
| Analgesia | D000698 | — | — | 1 | — | — | — | 4 | 5 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | — | — | 3 | 5 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | 4 | 5 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | 4 | 5 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | 1 | — | — | — | 3 | 4 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | — | — | — | 2 | 3 |
| Musculoskeletal pain | D059352 | — | — | 1 | — | — | — | 2 | 3 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | — | — | — | 2 | 3 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 2 | — | — | — | 1 | 3 |
Show 31 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 10 | 10 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 9 | 9 |
| Hyperhidrosis | D006945 | HP_0000975 | — | — | — | — | — | 9 | 9 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 9 | 9 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 8 | 8 |
| Hyperkinesis | D006948 | HP_0000752 | — | — | — | — | — | 5 | 5 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | — | — | 5 | 5 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 5 | 5 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 5 | 5 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 5 | 5 |
Show 425 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Liothyronine |
| INN | liothyronine |
| Description | 3,3',5-triiodo-L-thyronine is an iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism. It has a role as a thyroid hormone, a human metabolite and a mouse metabolite. It is an iodophenol, a 2-halophenol and an iodothyronine. It is a conjugate acid of a 3,3',5-triiodo-L-thyroninate. It is a tautomer of a 3,3',5-triiodo-L-thyronine zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 6893-02-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1544 |
| ChEBI ID | 18258 |
| PubChem CID | 5920 |
| DrugBank | DB00279 |
| UNII ID | 06LU7C9H1V (ChemIDplus, GSRS) |
Target
Agency Approved
THRA
THRA
Organism
Homo sapiens
Gene name
THRA
Gene synonyms
EAR7, ERBA1, NR1A1, THRA1, THRA2
NCBI Gene ID
Protein name
thyroid hormone receptor alpha
Protein synonyms
c-erbA protooncogene, c-erbA-1, c-erbA-alpha, EAR-7, ERBA-related 7, Nuclear receptor subfamily 1 group A member 1, thyroid hormone receptor alpha 1, thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian), triiodothyronine receptor, V-erbA-related protein 7
Uniprot ID
Mouse ortholog
Thra (21833)
thyroid hormone receptor alpha (Q99146)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Liothyronine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,273 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adthyza, Adthyza thyroid, Cytomel, Np thyroid 60, Np thyroid 90
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,095 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use